Tumor types selected: NSCLC, CRC, GE, RCC, TNBC, Ovarian.AB680: hCD73 IC50 (CD8 T cells): 0.008 nM; Ki (soluble CD73): 0.005 nM; reversal of AMP-mediated inhibition of T-cell activation in MLR, IC50 ~ 3 nM; inhibition of soluble CD73 (human serum), IC50 ~16 nM; projected human half-life: ≥ 4 days; projected clinical dosing to maintain >90% CD73 inhibition: ≤ 15 mg q2w. This evidence concerns the gene NT5E and non-small cell lung carcinoma.